-
Aggressive approach to CVD reduces MI, folic acid and vitamin B12 for CAD, corticosteroids for acute exacerbations of COPD, prescription drug abuse among young adults, and ARBs and cancer risk.
-
A systematic review of 9 studies showed that the COX-2 inhibitor celecoxib and ibuprofen cause less upper GI bleeding than other NSAIDs. Diclofenac, meloxicam, ketoprofen, indomethacin, and naproxen have intermediate risk. Piroxicam and ketorolac have the highest risk. In general, drugs that have a long half-life or slow-release formulation have the greatest risk of GI bleeding.
-
There is no difference in rates of treatment failure, death, or readmission for COPD between patients treated with oral or intravenous steroids for exacerbation of COPD, but the IV route may be associated with increased cost and length of stay.
-
The first receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor has been approved for the treatment of osteoporosis.
-
Fibrates: Generally safe, but do they improve outcomes? According to this meta-analysis, the answer to the question above very much depends upon which outcome you believe is important.
-
Get ready to add another option to the list of emergency contraception (EC) methods. The Food and Drug Administration has approved ella (ulipristal acetate, UPA) tablets.
-
While vaginitis usually is considered a minor nuisance, many women experience chronic symptoms that persist or recur after treatment. What can clinicians do?
-
Good news! Scientists have discovered two potent human antibodies that can neutralize more than 90% of known global HIV strains from infecting human cells in the laboratory, and they have demonstrated how one of these disease-fighting proteins achieves this action.
-
Your next patient is a recently divorced 48-year-old mother of two. Her menstrual periods have become somewhat irregular, and she reports occasional hot flashes and night sweats.
-
The search for a female-controlled form of HIV prevention just took a giant step. Results of a Phase IIB trial of a tenofovir gel indicate that use of the gel before and after sex provided moderate protection against sexually transmitted HIV.
